Buflomedil, sold under the brand name Loftyl, is a vasoactive drug used to treat claudication or the symptoms of peripheral arterial disease. It is currently not approved by the Food and Drug Administration (FDA) for use in the United States.

Pharmacology

Buflomedil acts as a non-selective or dual α1- and α2-adrenergic receptor antagonist and as a weak calcium channel blocker.[1]

Toxicity

This drug has been suspended from marketing in the European Union, because of concerns about severe neurological and cardiac toxicity.[2][3] In its press release dated 17 November 2011 EMA suggested that doctors "should stop using buflomedil and consider alternative treatment options". The European Commission advised all member states to revoke marketing authorisation.[4]

Various adverse effects have been reported to the FDA.[5]

Synthesis

Patent:[6] China1 China2

Acylation between 1,3,5-trimethoxybenzene [621-23-8] (1) and 4-pyrrolidinobutyronitrile [35543-25-0] (2) occurs in chlorobenzene solvent in the presence of gaseous hydrochloric acid to give Bufomedil (3). This is a demonstration of the Hoesch reaction.

References

  1. ↑ Bouskela E, Cyrino FZ (1997). "Effects of a calcium antagonist and of the adrenergic system on spontaneous vasomotion and mean arteriolar diameter in the hamster cheek pouch: influence of buflomedil". Int J Microcirc Clin Exp. 17 (4): 164–174. doi:10.1159/000179225. PMID 9378566.
  2. ↑ "Buflomedil-Containing Drugs May Be Suspended in EU". Medscape. Retrieved 20 February 2023.
  3. ↑ Archived copy EMA Archived 23 January 2012 at the Wayback Machine
  4. ↑ "Buflomedil durchf beschluss" (PDF). bfarm.de (in German). February 2012. Retrieved 20 February 2023.
  5. ↑ "Drug cite". Archived from the original on 4 March 2016. Retrieved 18 November 2011.
  6. ↑ DE2122144 idem Louis Lafon, U.S. patent 3,895,030 (1975 to Orsymonde);
source: https://en.wikipedia.org/wiki/Buflomedil